Title Association of aspartate aminotransferase with mortality in hemodialysis patients

Background. Liver disease is a common comorbid condition in maintenance hemodialysis (MHD) patients and may be associated with poor survival. The relationship between aspartate aminotransferase (AST) and survival has not yet been addressed in these patients. We hypothesized that higher AST level is associated with higher death risk in MHD patients. Methods. A 5-year (January 2007–December 2011) cohort of 109 718MHDpatients was studied in theUSA in dialysis clinics where ASTwasmeasured in at least 50% of all outpatients in the baseline calendar quarter. Survival models were adjusted for demographic variables, and available clinical and laboratory surrogates of malnutrition-inflammation complex, and cubic survival splines were plotted. Results. A linear association existed between baseline serum AST levels and mortality. Increasing AST of >20 IU/L was incrementally and almost linearly associated with higher death risk at all levels of adjustment. In fully adjusted models, AST levels of ≥40 IU/L were associated with the highest risk of mortality (hazard ratio: 1.46, 95% CI: 1.38–1.54). Low AST levels (<15 IU/L) were associated with increased death risk only in fully adjusted models examining hepatitis C virus-positive patients. Conclusions.Higher AST level of >20 IU/L is incrementally associated with higher mortality in MHD patients whereas AST in the 15–20 IU/L range is associated with the greatest survival. These findings suggest that the assessment of liver function and improving liver disease may confer survival benefit to MHD patients.

[1]  K. Kalantar-Zadeh,et al.  Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans , 2015, Hepatology.

[2]  W. Rathmann,et al.  Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States , 2014, BMJ : British Medical Journal.

[3]  T. Jørgensen,et al.  Vitamin D status, liver enzymes, and incident liver disease and mortality: a general population study , 2014, Endocrine.

[4]  A. Linneberg,et al.  Does liver damage explain the inverse association between vitamin D status and mortality? , 2013, Annals of epidemiology.

[5]  G. Willemsen,et al.  The Genetic Architecture of Liver Enzyme Levels: GGT, ALT and AST , 2013, Behavior genetics.

[6]  E. Lopes,et al.  Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis , 2012 .

[7]  K. Kalantar-Zadeh,et al.  Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. , 2010, Kidney international. Supplement.

[8]  K. Kalantar-Zadeh,et al.  Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[9]  S. Greenland,et al.  Hepatitis C virus and death risk in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.

[10]  K. Kalantar-Zadeh,et al.  Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[12]  J. Hoofnagle,et al.  Hepatitis C and renal disease: an update. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  A. Kirk,et al.  Hepatitis C Virus Seropositivity at the Time of Renal Transplantation in the United States: Associated Factors and Patient Survival , 2001, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  L. van Doorn,et al.  The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. , 2000, The Journal of infectious diseases.

[15]  T. Tsai,et al.  Viral hepatitis in continuous ambulatory peritoneal dialysis patients in an endemic area for hepatitis B and C infection: the Taiwan experience. , 1997, Blood purification.

[16]  C. Yen,et al.  Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  H. Hayashi,et al.  Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. , 1995, Gastroenterology.

[18]  T. Matsumata,et al.  The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. , 1995, Clinical nephrology.

[19]  Y. Berland,et al.  Hepatitis C virus infection among chronic dialysis patients in the south of France: a collaborative study. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  R. Reynolds,et al.  Vitamin B6 requirements of patients on chronic peritoneal dialysis. , 1989, Kidney international.

[21]  M. Swendseid,et al.  Daily requirement for pyridoxine supplements in chronic renal failure. , 1981, Kidney international.

[22]  M. Kleiner,et al.  Vitamin B6 deficiency in maintenance dialysis patients: metabolic effects of repletion. , 1980, The American journal of clinical nutrition.

[23]  B. Teehan,et al.  Plasma pyridoxal-5'-phosphate levels and clinical correlations in chronic hemodialysis patients. , 1978, The American journal of clinical nutrition.

[24]  C. Wagner,et al.  Increased plasma clearance of pyridoxal 5'-phosphate in vitamin B6-deficient uremic man. , 1977, The Journal of laboratory and clinical medicine.

[25]  H. Conn,et al.  Observations on decreased serum glutamic oxalacetic transaminase (SGOT) activity in azotemic patients. , 1976, Annals of internal medicine.

[26]  C. Wagner,et al.  Vitamin B6 deficiency in uremia. , 1975, The American journal of clinical nutrition.

[27]  C. Wagner,et al.  Decreased aspartate aminotransferase ("SGOT") activity in serum of uremic patients. , 1974, Clinical chemistry.

[28]  H. Grosse-wilde,et al.  Vitamin B6 deficiency in uremia and its implications for the depression of immune responses. , 1974, Kidney international.

[29]  N. Coplon,et al.  Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis. , 1972, Clinical chemistry.